Halozyme CEO Helen Torley sells USD 4.13 million in common shares

• Halozyme: President and CEO Helen Torley exercised options for 60,000 common shares at $18.41 on Aug. 17-19, 2026.
• She sold 59,000 common shares over the same period at weighted average prices of about $98.96 to $107.77.
• Directly held common shares ended at 767,780 following the transactions.
• Options to purchase common stock fell to 141,552, reflecting the three exercises.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001159036-26-000108), on August 19, 2026, and is solely responsible for the information contained therein.